Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
|
By LabMedica International staff writers Posted on 24 Jun 2021 |

Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its wide range of VITROS diagnostic testing and automation solutions at MEDLAB Middle East 2021.
Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.
Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.
Related Links:
Ortho Clinical Diagnostics
Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.
Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.
Related Links:
Ortho Clinical Diagnostics
Latest MEDLAB 2021 News
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
Cerebrovascular disease damages blood vessels in the brain and can contribute to tissue injury, microbleeds, white matter damage, stroke, cognitive decline, and dementia. Identifying people at higher risk... Read more
Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
B-cell non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), requires accurate identification to guide further evaluation, monitoring, and treatment. In 2026, an estimated 79,320 people in the U.... Read moreMolecular Diagnostics
view channel
DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce healthy blood cells normally. Treatment selection can be challenging because clinicians cannot reliably predict which... Read more
Circulating Tumor DNA Test Identifies Complete Immunotherapy Responders
Immune checkpoint inhibitors have transformed treatment for many metastatic cancers, with some patients achieving durable disease control. However, clinicians remain uncertain about how long therapy should... Read moreHematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more
Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read moreMicrobiology
view channel
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences applications. The transaction involved a cash payment of USD 240 million... Read more
New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more








.jpg)